Leadership Team
Management
Cory Berkland, PhD
Dr. Berkland serves as Chairman of the Board, Officer, and Co-Founder of Bond Biosciences. He is also a Professor of Biomedical Engineering and Chemistry at Washington University in St. Louis.
Dr. Berkland has experience founding, growing, and exiting pharmaceutical companies including Orbis Biosciences (acquired by Adare Pharmaceuticals) and Savara Pharmaceuticals (NASDAQ:SVRA). Dr. Berkland served in leadership roles at each of these companies. He also has experience working in venture capital as an entrepreneur-in-residence at Sofinnova Investments in 2014.
Mike Riley, MSc, JD
Michael Riley is a member of the board of directors, Officer, Corporate Secretary, Treasurer and Co-Founder of Bond Biosciences.
He is a licensed U.S. patent attorney and has represented numerous pharmaceutical companies, both public and private, with a focus on patent strategy, lifecycle management, and legal operations.
In addition to managing his law practice, Mr. Riley also has extensive experience working in the areas of Corporate Development, Business Development, and Operations for life science companies.
Board of Directors
Tim Opler, PhD
Director
Dr. Timothy Opler is a Co-Founder of Bond Biosciences. Dr. Opler raised the Seed Round of investment and provides ongoing financial support for the company.
He is a Managing Director at Stifel’s Global Healthcare Group. Tim Co-Founded Torreya Partners and became part of Stifel through a 2023 acquisition.
Dr. Opler has 24 years of experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on the life sciences sector and has completed more than 150 financing, licensing, and merger and acquisition (M&A) transactions across the industry, with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.
Before co-founding Torreya, Dr. Opler was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, he was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.
Mike Beckloff
Director
Michael Beckloff has 35 years of experience in the pharmaceutical, biologics, and medical device industries, with a focus on product development and regulatory sciences. His company, Beckloff Associates, a preeminent global consulting group, employed over 100 pharmaceutical and regulatory scientists, providing service to over 200 clients worldwide. He has worked on numerous approved NDAs, ANDA, and MAAs.
Cardinal Health acquired Beckloff Associates in 2004, where Mr. Beckloff continued until transitioning to Silvergate Pharmaceuticals as Chief Development Officer, with a focus on developing and delivering high-quality pediatric drug products. He is responsible for all R&D functions, including new product development and approval, and his team of highly skilled drug development professionals has been responsible for guiding the development of all of Silvergate products, resulting in five approved and commercial NDA drug products.
Mr. Beckloff received his Cellular Biology Degree from the University of Kansas.
Cory Berkland, PhD
Chairman
Mike Riley, MSc, JD
Director
Scientific Advisory Board
Peter Schultz, PhD
Peter Schultz, PhD, has made innovative and pioneering contributions to the interface between chemistry and biology, notably the exploitation of molecular diversity in the synthesis of new medicines and materials, and the rational expansion of the genetic code.
Dr. Schultz has demonstrated that traditional chemical tools used together with modern cellular and molecular biology methods can enable chemists to manipulate cellular machinery in amazing new ways. For example, his work has allowed us to add new building blocks to the genetic code, removing a billion-year constraint on living organisms.
He has also harnessed molecular diversity to create new catalysts, medicines and materials—first in reprogramming the immune system to make enzyme-like catalysts, and more recently developing and applying the use of large combinatorial libraries to find new materials and innovative drugs for aging, cancer, and infectious disease.
Coauthor of over 600 scientific publications, Dr. Schultz has trained over 300 coworkers and is currently President of Scripps Research and holds the Sam Skaggs Chair. He is a founder of nine companies that have pioneered the application of molecular diversity technologies to address multiple challenges in human health and materials science.
Curtis Scribner, MD
Curtis Scribner, MD, is a board certified internal medicine specialist with very long experience in drug development as a clinical investigator, regulatory reviewer, and strategic product life cycle consultant.
Dr. Scribner spent 10 years at the Center for Biologics Evaluation and Research (CBER), FDA, reviewing all phases of clinical development (discovery, preclinical testing, clinical trials, and regulatory) in a wide breadth of areas (blood, plasma, recombinant proteins, cells, tissues, vaccines, etc.). He worked for six years in a small venture-based drug, biologic and combination development company (BioMedicines/Intarcia) as the Chief Regulatory Officer.
He has more than 20 years of experience as a consultant to drugs and biologics companies working on everything from discovery and preclinical models through clinical trials, Data Safety Monitoring Committees and strategic and operational regulatory interactions in the US (FDA) and Europe (EMA and Member States).
He has extensive experience in oncology, hepatology, infectious disease, rheumatology, immunology, very rare and Orphan diseases and gene therapy.